Affinage

RNASEL

2-5A-dependent ribonuclease · UniProt Q05823

Length
741 aa
Mass
83.5 kDa
Annotated
2026-04-28
74 papers in source corpus 18 papers cited in narrative 18 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

RNASEL encodes a 2-5A-dependent endoribonuclease that serves as the terminal effector of the OAS innate immune pathway, cleaving single-stranded viral and cellular RNAs upon activation by 2',5'-oligoadenylates synthesized in response to double-stranded RNA. Binding of 2-5A to ankyrin repeats 6–9 induces RNase L dimerization and activation of its C-terminal ribonuclease domain, while the ankyrin repeats normally hold the enzyme in a latent state (PMID:10090396, PMID:33065920). Beyond antiviral defense—where it synergizes with OAS3 and ZAP to restrict CpG/UpA-high viruses (PMID:31276592)—RNase L mediates antibacterial immunity by promoting proinflammatory cytokine production and bacterial clearance (PMID:19075243), induces apoptosis through JNK signaling (PMID:15604285), drives cellular senescence with consequences for organismal lifespan (PMID:17130839), promotes adipocyte differentiation by destabilizing Pref-1 mRNA (PMID:27831565), and maintains barrier function against viral entry through a catalysis-independent interaction with filamin A (PMID:26760998). RNase L expression is post-transcriptionally regulated by HuR-mediated mRNA stabilization via 3'-UTR AU-rich elements and by miR-29 and miR-146a-mediated repression (PMID:17237228, PMID:23113544, PMID:36286041).

Mechanistic history

Synthesis pass · year-by-year structured walk · 14 steps
  1. 1999 High

    Defining the activation mechanism: the question of how 2-5A controls RNase L activity was resolved by showing that ankyrin repeats 6–9 serve as an autoinhibitory 2-5A-sensing module, while the C-terminal kinase-homology and ribonuclease domains are constitutively active when expressed alone.

    Evidence Domain truncation mutants expressed via vaccinia virus recombinants in cultured cells with functional activity comparison

    PMID:10090396

    Open questions at the time
    • Atomic-resolution structure of 2-5A binding within ankyrin repeats not yet determined in this study
    • Dimerization mechanism not addressed
  2. 2002 High

    Establishing functional consequences of a disease-associated variant: the R462Q polymorphism was shown to reduce enzymatic activity approximately threefold, linking reduced RNase L function to hereditary prostate cancer susceptibility.

    Evidence In vitro enzymatic activity assay comparing wild-type and R462Q recombinant proteins

    PMID:12415269

    Open questions at the time
    • Structural basis for reduced activity of R462Q not determined
    • Whether reduced activity alone is sufficient to drive tumorigenesis unclear
  3. 2004 High

    Demonstrating RNase L as a direct mediator of apoptosis: RNase L was shown to be required for apoptotic responses to 2-5A and topoisomerase I inhibitor/TRAIL, operating through JNK signaling, and its inhibitor RLI modulates this activity.

    Evidence Stable siRNA knockdown of RNase L in DU145 prostate cancer cells; apoptosis assays with multiple stimuli; JNK inhibitor experiments

    PMID:15604285

    Open questions at the time
    • Direct JNK activation mechanism by RNase L not identified
    • Whether RNA cleavage products mediate JNK activation unknown
  4. 2004 Medium

    Revealing a non-canonical RNA substrate: RNase L was found to selectively regulate mitochondrial DNA-encoded mRNA stability without affecting nuclear-encoded transcripts, expanding its known substrate repertoire beyond viral RNA.

    Evidence RNase-L knockout vs. wild-type mouse embryo fibroblasts; actinomycin D chase; RNase-L overexpression

    PMID:15522195

    Open questions at the time
    • Direct cleavage of mt-mRNAs by RNase L not demonstrated
    • Mechanism of selectivity for mt-mRNAs over nuclear mRNAs unknown
    • Single study without independent replication
  5. 2006 High

    Expanding RNase L biology to senescence and aging: RNase L was shown to induce cellular senescence in primary fibroblasts and apoptosis in transformed cells, with RNase-L-null mice living ~32% longer, establishing RNase L as a determinant of replicative lifespan.

    Evidence Ectopic expression, RNase-L knockout fibroblasts, 2-5A activation, SA-β-gal assays, BrdU incorporation, mouse lifespan studies

    PMID:17130839

    Open questions at the time
    • Molecular targets whose cleavage triggers senescence not identified
    • Whether senescence function is separable from antiviral function unclear
  6. 2007 High

    Defining post-transcriptional control of RNASEL expression: HuR was identified as a stabilizer of RNASEL mRNA via binding to AU-rich elements 7 and 8 in the 3'-UTR, directly linking mRNA stability regulation to antiviral output.

    Evidence 5'-RACE; chimeric reporter constructs; deletion analysis; HuR co-transfection; mRNA stability assays; HuR-RNase L mRNA co-IP; antiviral assays

    PMID:17237228

    Open questions at the time
    • Signals that regulate HuR binding to RNASEL mRNA not defined
    • Whether other RNA-binding proteins compete at these AREs unknown
  7. 2008 High

    Establishing an antibacterial role: RNase-L-null mice showed dramatically increased mortality from B. anthracis and E. coli infection due to impaired proinflammatory cytokine induction and compromised endosomal bacterial killing via cathepsin E.

    Evidence RNase-L knockout mouse infection models; bacterial load quantification; cytokine measurements; cathepsin-E expression analysis

    PMID:19075243

    Open questions at the time
    • Whether RNase L cleaves bacterial RNA directly in vivo not shown
    • Mechanism linking RNase L to cathepsin-E regulation not defined
  8. 2012 High

    Identifying miRNA-mediated regulation: the miR-29 family was shown to repress RNase L protein via four 3'-UTR target sites, and RNase L knockdown in CML cells inhibited proliferation, revealing a context-dependent oncogenic role.

    Evidence Luciferase reporter with RNASEL 3'-UTR; site mutagenesis; stable knockdown in K562 cells; xenograft tumor model

    PMID:23113544

    Open questions at the time
    • How oncogenic and tumor-suppressive roles are reconciled across cancer types not resolved
    • Whether miR-29 regulation occurs in normal hematopoiesis unknown
  9. 2013 High

    Demonstrating a protective role in intestinal immunity: RNase L was required for innate immune responses to intestinal damage, protecting against colitis and colitis-associated cancer through IFN-β and proinflammatory cytokine production triggered by bacterial RNA.

    Evidence RNase-L knockout mice; DSS colitis and DSS/AOM cancer models; cytokine profiling; bacterial RNA stimulation

    PMID:23567782

    Open questions at the time
    • Identity of specific bacterial RNA species sensed not determined
    • Role of RNase L in human IBD not established
  10. 2014 Medium

    Resolving the structural basis of activation: two 2-5A molecules were shown to bridge ankyrin domains of two RNase L subunits in opposite orientations, with pseudokinase domain nucleotide binding strengthening the dimer and activating the ribonuclease domain.

    Evidence Structural and biochemical studies of RNase L dimerization (cited through review)

    PMID:33065920

    Open questions at the time
    • Primary structural data not directly available in this corpus
    • How dimerization is reversed during pathway downregulation not defined
  11. 2016 Medium

    Identifying a catalysis-independent function: RNase L was found to interact with filamin A to maintain cellular barriers against viral entry independently of its ribonuclease activity, demonstrating a non-enzymatic role.

    Evidence Co-immunoprecipitation/pulldown; viral entry assays; catalytic mutant analysis

    PMID:26760998

    Open questions at the time
    • Structural basis of RNase L–filamin A interaction not determined
    • Whether other cytoskeletal partners contribute to barrier function unknown
    • Finding summarized in a review, primary data citation indirect
  12. 2016 High

    Demonstrating a role in adipocyte differentiation: RNase L was shown to directly bind and destabilize Pref-1 mRNA, an adipogenesis inhibitor, promoting differentiation through FAK/ERK/SOX9 signaling.

    Evidence siRNA knockdown; RNase L immunoprecipitation of Pref-1 mRNP; mRNA decay assay; rescue experiments; xenograft and animal models

    PMID:27831565

    Open questions at the time
    • Whether 2-5A activation is required for Pref-1 cleavage not shown
    • Physiological signals activating RNase L during adipogenesis not identified
  13. 2019 High

    Delineating pathway specificity in antiviral defense: OAS3 (not OAS1) was established as the upstream activator of RNase L for restriction of CpG/UpA-high viruses, acting in synergy with the ZAP pathway.

    Evidence ZAP, RNase L, and OAS3 knockout cell lines; viral replication assays with CpG/UpA-modified echovirus 7 mutants

    PMID:31276592

    Open questions at the time
    • Whether OAS3 specificity extends to other viral families not tested
    • Mechanism of ZAP–RNase L synergy at the molecular level not defined
  14. 2022 Medium

    Adding miR-146a as a second miRNA repressor and linking RNase L expression to hormonal regulation: miR-146a-5p directly targets the RNASEL 3'-UTR, and sex hormones differentially modulate RNase L levels through transcriptional (estradiol) and post-transcriptional (testosterone/miR-146a) mechanisms.

    Evidence Luciferase reporter; miR-146a mimic transfection; hormone treatment in melanoma cell lines; qPCR and western blot

    PMID:36286041

    Open questions at the time
    • Hormonal regulation not confirmed outside melanoma
    • Whether miR-146a regulation contributes to sex differences in antiviral immunity not tested
    • Single lab study

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include how RNase L selects specific cellular mRNA substrates (mt-mRNAs, Pref-1) versus bulk RNA, the structural basis of its catalysis-independent barrier function through filamin A, and how its pro-apoptotic/senescence and context-dependent oncogenic activities are coordinated in different tissues.
  • No systematic identification of endogenous cleavage substrates across tissues
  • Structural model of RNase L–filamin A complex lacking
  • Mechanism reconciling tumor-suppressive and oncogenic roles unresolved

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140098 catalytic activity, acting on RNA 5 GO:0098772 molecular function regulator activity 3 GO:0008092 cytoskeletal protein binding 1
Localization
GO:0005829 cytosol 2
Pathway
R-HSA-168256 Immune System 3 R-HSA-8953854 Metabolism of RNA 3 R-HSA-5357801 Programmed Cell Death 2
Partners
FLNAHURLNX1OAS2OAS3

Evidence

Reading pass · 18 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1999 Full activation of RNase L requires binding of 2-5A oligonucleotides within ankyrin repeats 6 to 9 (amino acid positions 212-339). The protein kinase and ribonuclease domains (amino acids 340-741) are sufficient for constitutively active, 2-5A-unresponsive enzyme, demonstrating that ankyrin repeats act as key modulators of RNase L activity. Expression of truncated RNase L forms via vaccinia virus recombinants in cultured cells, with and without co-expression of 2-5A synthetase; functional activity comparison Journal of interferon & cytokine research High 10090396
2002 The RNASEL variant Arg462Gln has approximately three times less enzymatic (RNase) activity than the wild-type protein. Enzymatic activity assay comparing wild-type and R462Q variant proteins Nature genetics High 12415269
2004 RNase L mediates apoptosis of prostate cancer cells in response to 2-5A, topoisomerase I inhibitor/TRAIL combination, and this apoptotic signaling involves c-Jun N-terminal kinase (JNK). RNase L-deficient DU145 cells were highly resistant to apoptosis from these stimuli, while knockdown of the RNase L inhibitor RLI (HP68) enhanced apoptosis. Stable siRNA knockdown of RNase L in DU145 prostate cancer cells; apoptosis assays with 2-5A, camptothecin/TRAIL combinations; JNK inhibitor experiments Cancer research High 15604285
2004 RNase L regulates the stability of mitochondrial DNA-encoded mRNAs (mt-mRNAs). In RNase-L-null mouse embryo fibroblasts, monensin-induced decrease in mt-mRNA half-life was reduced (>6h vs. 3h in wild-type), and induction of RNase-L further decreased mt-mRNA half-life to 1.5h. Nuclear-encoded beta-actin mRNA stability was unaffected. RNase-L(-/-) vs. wild-type mouse embryo fibroblasts; actinomycin D transcription termination assay; RNase-L overexpression in 3T3 fibroblasts Biochemical and biophysical research communications Medium 15522195
2005 BRCA1 and STAT1 are required for IFN-gamma-induced transcriptional activation of 2,5-OAS, the upstream activator of RNase L, positioning BRCA1 as an upstream regulator of the OAS/RNase L apoptotic pathway. IFN-gamma-induced apoptosis was dependent on 2,5-OAS induction. Transient transfection of 2,5-OAS into breast cancer cell lines (colony growth/apoptosis assays); siRNA/dominant-negative BRCA1 and STAT1 knockdown; functional apoptosis assays Oncogene Medium 15940267
2006 RNase L induces cellular senescence: ectopic expression of RNase L induced senescent morphology, decreased DNA synthesis, increased SA-β-galactosidase activity, and accelerated replicative senescence. RNase-L-null fibroblasts showed retarded senescence. Activation of endogenous RNase L by 2-5A induced senescence in parental WI38 fibroblasts but apoptosis in SV40-transformed cells. RNase-L(-/-) mice survived 31.7% longer than wild-type mice. Ectopic RNase L expression; RNase-L(-/-) vs. wild-type fibroblasts; 2-5A transfection; SA-β-gal assays; BrdU incorporation; mouse lifespan studies Oncogene High 17130839
2007 The 3'-UTR of RNASEL mRNA mediates post-transcriptional regulation of RNase L expression by decreasing mRNA stability. Eight AU-rich elements (AREs) were identified; AREs 7 and 8 serve a positive regulatory function. The RNA-binding protein HuR stabilizes RNase-L mRNA by binding within the region of AREs 7 and 8, enhancing RNase-L expression and antiviral activity. 5'-RACE; chimeric beta-globin-3'-UTR reporter constructs; deletion analysis; HuR co-transfection; mRNA stability assays; immunoprecipitation of HuR-RNase-L mRNA complex; antiviral activity assays The Journal of biological chemistry High 17237228
2008 RNase L is required for the antibacterial immune response. RNase-L(-/-) mice showed dramatically increased mortality after Bacillus anthracis and E. coli challenge due to increased bacterial load and compromised immune response. RNase-L is required for optimal induction of proinflammatory cytokines (TNF-alpha, IL-6, IL-12) and regulates cathepsin-E expression and endosome-associated activities that eliminate internalized bacteria. RNase-L(-/-) mouse infection models (B. anthracis, E. coli); bacterial load quantification; cytokine measurements; cathepsin-E expression analysis Proceedings of the National Academy of Sciences of the United States of America High 19075243
2009 NOD2 interacts with 2'-5'-oligoadenylate synthetase type 2 (OAS2), an upstream activator of RNase L. This interaction was confirmed by immunoprecipitation of endogenous OAS2 with NOD2 in THP-1 cells, and overexpression of NOD2 enhanced RNase-L activity in poly(I:C)-treated cells. Proteomics/pulldown; co-immunoprecipitation in HEK and THP-1 cells; RNase-L activity assay after NOD2 overexpression and poly(I:C) treatment Molecular immunology Medium 19853919
2012 The miR-29 family represses RNase-L protein expression via four target sites within the RNASEL 3'-UTR. In K562 CML cells, RNase-L knockdown inhibits proliferation in vitro and tumor growth in a xenograft model, revealing an oncogenic role for RNase-L in CML. Luciferase reporter with RNASEL 3'-UTR; site mutagenesis; stable RNase-L knockdown in K562 cells; in vitro proliferation assay; xenograft tumor model Journal of interferon & cytokine research High 23113544
2013 RNase-L promotes the innate immune response to intestinal damage and protects against experimental colitis and colitis-associated cancer. RNase-L(-/-) mice showed higher clinical scores, delayed leukocyte infiltration, reduced IFN-beta, TNF-alpha, IL-1beta, and IL-18, and increased tumor burden after DSS/AOM treatment. Bacterial RNA triggered IFN-beta production in an RNase-L-dependent manner. RNase-L(-/-) mice with DSS-induced colitis and DSS/AOM colitis-associated cancer model; histology; immunohistochemistry; cytokine qRT-PCR and ELISA; bacterial RNA stimulation Inflammatory bowel diseases High 23567782
2016 RNase-L binds to filamin A, an actin-binding protein, and this interaction maintains the cellular barrier to viral entry independently of RNase-L catalytic function. RNase-L also interacts with LNX (ligand of numb protein X), an E3 ubiquitin ligase and scaffolding protein that regulates tight junction proteins. Co-immunoprecipitation/pulldown; functional viral entry assays; catalytic mutant analysis International journal of molecular sciences Medium 26760998
2016 RNase-L promotes adipocyte differentiation by destabilizing Pref-1 mRNA, an inhibitor of adipogenesis. RNase-L knockdown increased Pref-1 mRNA levels and reduced 3T3-L1 adipocyte differentiation; Pref-1 mRNA was detected in RNase-L immunoprecipitates; elevated RNase-L ribonuclease activity increased Pref-1 mRNA decay rate. Downstream signaling via FAK, ERK, and SOX9 was activated by RNase-L suppression. RNase-L siRNA knockdown; mRNA profiling; RNase-L immunoprecipitation of mRNP complexes; mRNA decay assay; siRNA rescue experiment; meta-analysis of public array datasets; animal models Cell death & disease High 27831565
2019 Attenuation of CpG-high and UpA-high RNA viruses requires OAS3 and RNase L (but not OAS1), acting in synergy with ZAP. Knockout of RNase L or OAS3 reversed the attenuation of CpG- and UpA-high echovirus 7 mutants even in the presence of abundant ZAP, demonstrating complementarity/synergy between the ZAP and OAS3/RNase-L pathways. ZAP, RNase L, and OAS3 knockout cell lines; viral replication assays with CpG/UpA-high mutants; pulldown assays for ZAP-RNA interaction Nucleic acids research High 31276592
2014 Two 2'-5' oligoadenylate molecules bridge ankyrin domains of two RNase L subunits bound in opposite orientations; binding of nucleotides to the pseudokinase domain further strengthens the dimer and imparts an active conformation to the ribonuclease domain. Structural analysis (referenced in review); biochemical studies of RNase L dimerization and activation Virologie (Montrouge, France) Medium 33065920
2022 miR-146a-5p directly targets the 3'-UTR of RNASEL mRNA to repress RNase-L protein expression in melanoma cells, as demonstrated by luciferase reporter assay. miR-146a overexpression repressed RNase-L protein and activated ERK1/2, supporting a pro-tumorigenic role. Sex hormones differentially regulate RNase-L: 17β-estradiol increased RNase-L expression transcriptionally, while testosterone decreased it post-transcriptionally via a mechanism involving miR-146a. Luciferase reporter with RNASEL 3'-UTR; miR-146a mimic transfection; qPCR; western blot; hormone treatment experiments in LM-20 and A375 melanoma cell lines Current issues in molecular biology Medium 36286041
2025 RNase L activation by the OAS pathway leads to cell death upon tonic type I IFN induction. ADAR1p150 suppresses OAS-RNaseL pathway activation (in addition to MDA5 and PKR pathways) to prevent immune sensing of self-dsRNAs, with RNaseL acting downstream of IFN-induced OAS activation. Adar1 mutant mice rescued by MDA5 and PKR loss; IFNβ treatment of HSPCs in vitro; IFNAR1 neutralization in vivo; cell line experiments with OAS-RNaseL pathway activation bioRxivpreprint Medium bio_10.1101_2025.10.14.682456
2025 RNase L activation upon dsRNA sensing inhibits NMD (nonsense-mediated decay) through translational blockade, creating a negative feedback loop that limits dsRNA sensing by reducing the dsRNA load and thus dampening IFN-beta induction, PKR and RNase L activation, and PIC-mediated cell death. RNaseL-deficient cell lines; PKR inhibition; NMD activity measurements; IFN-beta and ISG induction assays; dsRNA content measurements; IRF3 phosphorylation/translocation assays bioRxivpreprint Medium bio_10.1101_2025.05.09.652687

Source papers

Stage 0 corpus · 74 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2006 Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS pathogens 452 16609730
2002 RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nature genetics 216 12415269
2002 Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. American journal of human genetics 165 11941539
2002 A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. American journal of human genetics 99 12145743
2002 Analysis of the RNASEL gene in familial and sporadic prostate cancer. American journal of human genetics 94 12022038
2019 The role of ZAP and OAS3/RNAseL pathways in the attenuation of an RNA virus with elevated frequencies of CpG and UpA dinucleotides. Nucleic acids research 76 31276592
2004 Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 66 15534086
2005 Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene. British journal of cancer 61 15714208
2003 Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population. British journal of cancer 59 12915880
2004 HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand. Cancer research 57 15604285
2008 An essential role for the antiviral endoribonuclease, RNase-L, in antibacterial immunity. Proceedings of the National Academy of Sciences of the United States of America 52 19075243
2010 Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis 51 20576793
2014 RNase-L control of cellular mRNAs: roles in biologic functions and mechanisms of substrate targeting. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 49 24697205
2008 Germline mutation in RNASEL predicts increased risk of head and neck, uterine cervix and breast cancer. PloS one 49 18575592
2005 The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1- and interferon-gamma-mediated apoptosis. Oncogene 49 15940267
2005 Mapping of the human RNASEL promoter and expression in cancer and normal cells. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 45 16241858
2006 RNASEL gene polymorphisms and the risk of prostate cancer: a meta-analysis. Clinical cancer research : an official journal of the American Association for Cancer Research 44 17020975
2009 Nucleotide oligomerization domain-2 interacts with 2'-5'-oligoadenylate synthetase type 2 and enhances RNase-L function in THP-1 cells. Molecular immunology 43 19853919
2006 Role of 2-5A-dependent RNase-L in senescence and longevity. Oncogene 41 17130839
2016 The Roles of RNase-L in Antimicrobial Immunity and the Cytoskeleton-Associated Innate Response. International journal of molecular sciences 40 26760998
2010 Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 40 20086112
2005 RNASEL germline variants are associated with pancreatic cancer. International journal of cancer 40 15981205
2007 Post-transcriptional regulation of RNase-L expression is mediated by the 3'-untranslated region of its mRNA. The Journal of biological chemistry 39 17237228
2007 Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans. Clinical cancer research : an official journal of the American Association for Cancer Research 38 17908993
2005 Arg462Gln sequence variation in the prostate-cancer-susceptibility gene RNASEL and age of onset of hereditary non-polyposis colorectal cancer: a case-control study. The Lancet. Oncology 37 16054567
2002 Cleavage of Treponema denticola PrcA polypeptide to yield protease complex-associated proteins Prca1 and Prca2 is dependent on PrtP. Journal of bacteriology 32 12081957
2012 Regulation of human RNase-L by the miR-29 family reveals a novel oncogenic role in chronic myelogenous leukemia. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 31 23113544
2010 Contribution of HPC1 (RNASEL) and HPCX variants to prostate cancer in a founder population. The Prostate 30 20564318
2013 RNase-L deficiency exacerbates experimental colitis and colitis-associated cancer. Inflammatory bowel diseases 27 23567782
2013 Association of RNASEL and 8q24 variants with the presence and aggressiveness of hereditary and sporadic prostate cancer in a Hispanic population. Journal of cellular and molecular medicine 24 24224612
2004 RNase-L regulates the stability of mitochondrial DNA-encoded mRNAs in mouse embryo fibroblasts. Biochemical and biophysical research communications 23 15522195
2014 RNASEL and MIR146A SNP-SNP interaction as a susceptibility factor for non-melanoma skin cancer. PloS one 21 24699816
2006 RNASEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patients. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 21 16537704
2008 RNASEL and RNASEL-inhibitor variation and prostate cancer risk in Afro-Caribbeans. The Prostate 20 18189233
2007 Trans-fatty acid intake and increased risk of advanced prostate cancer: modification by RNASEL R462Q variant. Carcinogenesis 20 17234723
2007 The additive effect of p53 Arg72Pro and RNASEL Arg462Gln genotypes on age of disease onset in Lynch syndrome patients with pathogenic germline mutations in MSH2 or MLH1. Cancer letters 19 17224235
2015 Functional and Structural Consequences of Damaging Single Nucleotide Polymorphisms in Human Prostate Cancer Predisposition Gene RNASEL. BioMed research international 17 26236721
2013 A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 17 23382116
2007 DNA variation in MSR1, RNASEL and E-cadherin genes and prostate cancer in Poland. Urologia internationalis 17 17627168
2004 Mutational analysis of susceptibility genes RNASEL/HPC1, ELAC2/HPC2, and MSR1 in sporadic prostate cancer. Genes, chromosomes & cancer 17 14695991
2012 Pathologic effects of RNase-L dysregulation in immunity and proliferative control. Frontiers in bioscience (Scholar edition) 16 22202089
2010 Identification of cellular genes induced in human cells after activation of the OAS/RNaseL pathway by vaccinia virus recombinants expressing these antiviral enzymes. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 14 20038200
2011 Genetic variation in RNASEL and risk for prostate cancer in a population-based case-control study. The Prostate 13 21360564
2008 Molecular evolution of the prostate cancer susceptibility locus RNASEL: evidence for positive selection. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 13 18295551
2017 Sex-specific effect of RNASEL rs486907 and miR-146a rs2910164 polymorphisms' interaction as a susceptibility factor for melanoma skin cancer. Melanoma research 12 28654546
2011 Predictive value in the analysis of RNASEL genotypes in relation to prostate cancer. Prostate cancer and prostatic diseases 12 22083266
2007 Characterization of the equine 2'-5' oligoadenylate synthetase 1 (OAS1) and ribonuclease L (RNASEL) innate immunity genes. BMC genomics 12 17822564
2017 Human serum RNase-L level is inversely associated with metabolic syndrome and age. Cardiovascular diabetology 11 28399925
2016 A link between adipogenesis and innate immunity: RNase-L promotes 3T3-L1 adipogenesis by destabilizing Pref-1 mRNA. Cell death & disease 11 27831565
2008 Pathological aggressiveness of prostatic carcinomas related to RNASEL R462Q allelic variants. The Journal of urology 11 18289577
2018 Is RNASEL:p.Glu265* a modifier of early-onset breast cancer risk for carriers of high-risk mutations? BMC cancer 8 29422015
2017 Association of a common genetic variant in RNASEL and prostate cancer susceptibility. Oncotarget 8 29088852
2012 Positive selection on the gene RNASEL: correlation between patterns of evolution and function. Molecular biology and evolution 8 22513284
2011 RNASEL -1385G/A polymorphism and cancer risk: a meta-analysis based on 21 case-control studies. Molecular biology reports 8 21221811
2011 The effect of TP53 codon 72 and RNASEL codon 462 polymorphisms on the development of cervical cancer in Argentine women. Cancer genetics 8 21665181
2008 Analysis of the RNASEL/HPC1, and macrophage scavenger receptor 1 in Asian-Indian advanced prostate cancer. Urology 8 18436282
2006 The 471delAAAG mutation and C353T polymorphism in the RNASEL gene in sporadic and inherited cancer in Israel. Familial cancer 8 16944274
2004 Lack of association between RNASEL Arg462Gln variant and the risk of breast cancer. Anticancer research 8 15330212
1999 Full activation of RNaseL in animal cells requires binding of 2-5A within ankyrin repeats 6 to 9 of this interferon-inducible enzyme. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 8 10090396
2014 The OAS/RNaseL pathway and its inhibition by viruses. Virologie (Montrouge, France) 5 33065920
2006 An alternative spliced RNASEL variant in peripheral blood leukocytes. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 5 17115900
2022 Template-Independent Poly(A)-Tail Decay and RNASEL as Potential Cellular Biomarkers for Prostate Cancer Development. Cancers 4 35565367
2022 Carriage of mutations R462Q (rs 486907) and D541E (rs 627928) of the RNASEL gene and risk factors in patients with prostate cancer in Burkina Faso. BMC medical genomics 4 35655265
2005 Identification and characterization of rns4/vps32 mutation in the RNase T1 expression-sensitive strain of Saccharomyces cerevisiae: Evidence for altered ambient response resulting in transportation of the secretory protein to vacuoles. FEMS yeast research 3 15925308
2022 Human Melanoma Cells Differentially Express RNASEL/RNase-L and miR-146a-5p under Sex Hormonal Stimulation. Current issues in molecular biology 2 36286041
2019 Evidence from 40 Studies that 2 Common Single-Nucleotide Polymorphisms (SNPs) of RNASEL Gene Affect Prostate Cancer Susceptibility: A Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-Compliant Meta-Analysis. Medical science monitor : international medical journal of experimental and clinical research 2 31686670
2017 The RNASEL -1385G/A polymorphism is associated with risk of prostate cancer in Africans. OncoTargets and therapy 2 29317837
2012 Short communication: RNASEL alleles and susceptibility to infection by human retroviruses and hepatitis viruses. AIDS research and human retroviruses 2 22356654
2019 RNASEL 1623A>C variant is associated with the risk of prostate cancer in African descendants. Journal of cellular biochemistry 1 30790337
2012 [RNASEL study of genetics of prostate cancer and its relation to clinical staging]. Actas urologicas espanolas 1 22464196
2009 [G138A polymorphism of the RNASEL gene and its association with the development of prostate cancer. Preliminary study]. Investigacion clinica 1 19961052
2025 Single nucleotide polymorphisms in the RNASEL gene are associated with acute and late adverse effects of radiotherapy and fatigue in patients with prostate adenocarcinoma. International journal of radiation biology 0 40456005
2025 ATR&RNASEL germline variants: novel findings in a case of familial cancer. Molecular genetics and genomics : MGG 0 41381960
2015 Age-related methylation profiles of equine blood leukocytes in the RNASEL locus. Journal of applied genetics 0 26553552